Privia Health price target lowered to $32 from $36 at Truist

Truist lowered the firm’s price target on Privia Health to $32 from $36 but keeps a Buy rating on the shares. The firm is updating its model to reflect Q3 results, its updated outlook for Q4, as well as an assumption around Medicare Advantage capitation contribution in the out years, the analyst tells investors in a research note. The addition of any large provider groups or an accelerated pace in Medicare Advantage value-based care could provide upside relative to estimates, the firm added.